BB Biotech

BB Biotech EBIT

The EBIT of BB Biotech (BION.SW) as of Nov 2, 2026 is 586.83 M CHF. In the previous year, EBIT was 84.40 M CHF — a change of 595.29% (higher).

EBIT

586.83 MCHF

YoY

595.29%

Last updated:

In 2025, BB Biotech's EBIT was 586.83 M CHF, a 595.29% increase from the 84.40 M CHF EBIT recorded in the previous year.

The BB Biotech EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT
Date
EBIT
Jan 1, 2021
-403.76 M CHF
Jan 1, 2022
-356.03 M CHF
Jan 1, 2023
-29.93 M CHF
Jan 1, 2024
84.40 M CHF
Jan 1, 2025
586.83 M CHF
Jan 1, 2026 (e)
179.11 M CHF
Jan 1, 2027 (e)
266.14 M CHF
Jan 1, 2028 (e)
125.82 M CHF
The BB Biotech EBIT history
YEAREBITYoY
est125.82 MCHF-52.72%
est266.14 MCHF+48.59%
est179.11 MCHF-69.48%
586.83 MCHF+595.29%
84.40 MCHF-382.01%
-29.93 MCHF-91.59%
-356.03 MCHF-11.82%
-403.76 MCHF-158.26%
693.01 MCHF+2.29%
677.50 MCHF-244.08%
-470.22 MCHF-168.33%
688.12 MCHF-183.01%
-828.93 MCHF-226.93%
653.08 MCHF-55.60%
1.47 BCHF+57.64%
932.97 MCHF+151.60%
370.82 MCHF-670.04%
-65.05 MCHF-55.53%
-146.27 MCHF-478.35%
38.66 MCHF-14.90%
45.43 MCHF-117.12%
-265.30 MCHF-142.33%
626.69 MCHF—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BB Biotech Revenue

BB Biotech Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2021
-396.22 M CHF
-403.76 M CHF
-404.81 M CHF
Jan 1, 2022
-351.23 M CHF
-356.03 M CHF
-357.81 M CHF
Jan 1, 2023
35,000.00 CHF
-29.93 M CHF
-206.61 M CHF
Jan 1, 2024
111.63 M CHF
84.40 M CHF
75.90 M CHF
Jan 1, 2025
76.81 M CHF
586.83 M CHF
578.13 M CHF
Jan 1, 2026 (e)
1.28 B CHF
179.11 M CHF
141.47 M CHF
Jan 1, 2027 (e)
1.28 B CHF
266.14 M CHF
210.20 M CHF
Jan 1, 2028 (e)
1.28 B CHF
125.82 M CHF
208.94 M CHF

BB Biotech Margins

BB Biotech stock margins

The BB Biotech margin analysis displays the gross margin, EBIT margin, as well as the profit margin of BB Biotech. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for BB Biotech.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
100.00 %
101.90 %
102.17 %
Jan 1, 2022
100.00 %
101.37 %
101.87 %
Jan 1, 2023
100.00 %
-85,508.57 %
-590,305.70 %
Jan 1, 2024
100.00 %
75.61 %
67.99 %
Jan 1, 2025
99.93 %
763.99 %
752.66 %
Jan 1, 2026 (e)
99.93 %
14.00 %
11.06 %
Jan 1, 2027 (e)
99.93 %
20.81 %
16.43 %
Jan 1, 2028 (e)
99.93 %
9.84 %
16.34 %

BB Biotech Stock analysis

What does BB Biotech do? BB Biotech AG is a Swiss investment company specializing in biotechnology and life sciences. The company was founded in 1993 and has been listed on the SIX Swiss Exchange since 1995. BB Biotech AG primarily invests in publicly traded companies in Europe and North America that are active in the biotechnology and healthcare industry. The business model of BB Biotech AG is based on a combination of active portfolio management and long-term investment strategy. The company invests in stocks of biotechnology and healthcare companies that typically do not yet generate profits but are developing promising products or technologies. BB Biotech AG focuses on high portfolio diversification to minimize risk. BB Biotech AG is divided into three business areas: biotechnology, pharmaceuticals, and medtech. The emphasis is on biotechnology, where the company invests in stocks of well-known biotech companies such as Celgene, Gilead Sciences, Regeneron, and Biogen. In the pharmaceutical sector, BB Biotech AG invests in large pharmaceutical companies like Roche, Novartis, or Pfizer. In the medtech sector, the company invests in companies specializing in the development of medical devices and instruments, such as Intuitive Surgical or Neurocrine Biosciences. BB Biotech AG provides added value to its investors through continuous monitoring of the companies in the portfolio and risk management. The company ensures that investors are always informed about the latest developments in the biotechnology and healthcare industry and regularly publishes reports about the portfolio. The portfolio of BB Biotech AG consists of over 30 different biotech, pharmaceutical, and medtech companies. The main holdings of BB Biotech AG are Celgene, Gilead Sciences, Biogen, Incyte, Vertex Pharmaceuticals, Regeneron, and Neurocrine Biosciences. Celgene is one of the world's leading biotech companies specializing in the development of drugs against cancer and other serious diseases. Gilead Sciences is a biotech company specializing in the research of new therapies for the treatment of infectious diseases such as HIV and hepatitis. Biogen is a biotech company specializing in the treatment of neurological disorders such as multiple sclerosis. Incyte is a biotech company specializing in the development of drugs against cancer and inflammatory diseases. Vertex Pharmaceuticals is a biotech company specializing in the treatment of cystic fibrosis. Regeneron is a biotech company specializing in the development of drugs against eye diseases such as macular degeneration and other serious diseases. Neurocrine Biosciences is a medtech company specializing in the development of drugs against sleep disorders and other neurological diseases. BB Biotech AG is an important player in the market for biotechnology and healthcare investments. Through smart selection of investment targets and systematic risk monitoring, the company has enabled investors to achieve high returns with comparatively low risk. Due to these factors, it is now one of the most important holdings in the biotechnology and healthcare sector. BB Biotech is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing BB Biotech's EBIT

BB Biotech's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of BB Biotech's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

BB Biotech's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in BB Biotech’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about BB Biotech stock

EBIT of BB Biotech is 586.83 M CHF in 2025.

EBIT of BB Biotech changed from 84.40 M CHF to 586.83 M CHF, representing a 595.29% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT BB Biotech since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's CHF is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's BB Biotech historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — BB Biotech

All Key Metrics — BB Biotech